Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The cancer groundshot: Going global before going to the moon

Choosing Wisely: Value added cancer care for India

15 - 16 Oct 2019

Published: 7 Nov 2019

Views: 3484

Rating:

Save

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Dr Bishal Gyawali presents a talk on 'The cancer groundshot: Going global before going to the moon' at the Choosing wisely: Value Added Cancer Care for India event in New Delhi.

Related Videos

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine...

Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht...

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy ( Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands )

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA...

Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ( Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA )

More from ecancer